KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Receivables (2016 - 2025)

Globus Medical's Receivables history spans 15 years, with the latest figure at $678.9 million for Q4 2025.

  • For Q4 2025, Receivables rose 21.74% year-over-year to $678.9 million; the TTM value through Dec 2025 reached $678.9 million, up 21.74%, while the annual FY2025 figure was $678.9 million, 21.74% up from the prior year.
  • Receivables reached $678.9 million in Q4 2025 per GMED's latest filing, up from $619.1 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $678.9 million in Q4 2025 to a low of $159.6 million in Q3 2021.
  • Average Receivables over 5 years is $381.3 million, with a median of $367.1 million recorded in 2023.
  • Peak YoY movement for Receivables: soared 154.71% in 2024, then decreased 0.04% in 2025.
  • A 5-year view of Receivables shows it stood at $164.4 million in 2021, then grew by 29.68% to $213.2 million in 2022, then skyrocketed by 135.99% to $503.2 million in 2023, then increased by 10.82% to $557.7 million in 2024, then increased by 21.74% to $678.9 million in 2025.
  • Per Business Quant, the three most recent readings for GMED's Receivables are $678.9 million (Q4 2025), $619.1 million (Q3 2025), and $611.6 million (Q2 2025).